SEC Filing Summary
Filing identity: The supplied filing is for Oculus Innovative Sciences, Inc. (now identified in the request metadata as Sonoma Pharmaceuticals, Inc.); it is not a filing under the Sonoma Pharmaceuticals name. Verify that this is the intended issuer.
Business context and reporting period
Form 10-Q for the quarter ended September 30, 2011, the second quarter of Oculus’s fiscal 2012, and the six months then ended. Oculus developed, manufactured, and marketed Microcyn-based wound-care products and operated a contract-testing laboratory. Financial statements are unaudited; dollar amounts below are in U.S. dollars.
Financial performance and condition
| Metric | Three months ended September 30, 2011 | Six months ended September 30, 2011 |
|---|---|---|
| Revenue | $3.663 million | $6.603 million |
| Gross profit | $2.778 million; approximately 75.8% margin | $4.727 million; approximately 71.6% margin |
| Operating expenses | $3.408 million | $7.375 million |
| Operating loss | $0.630 million | $2.648 million |
| Net loss | $0.839 million; $0.03 per share | $3.014 million; $0.11 per share |
| Operating cash flow | Not separately presented for the quarter | $(1.468) million |
- Six-month revenue comprised $6.100 million in product revenue and $0.503 million in service revenue. Product revenue grew 41% year over year; total revenue grew 40%.
- Cash and cash equivalents were $3.622 million at September 30, versus $4.371 million at March 31, 2011. Working capital was $2.715 million. The cash-flow statement reports a six-month net cash decrease of $0.749 million.
- Balance-sheet long-term debt, net of discounts, was $2.553 million in total: $0.852 million current and $1.701 million long term. Total liabilities were $7.899 million, against $7.763 million in assets; stockholders’ equity was negative $0.136 million.
- Management reported an accumulated deficit of $127.999 million. No operating margin, EBITDA, or formal full-year financial guidance is provided.
Changes versus prior comparable periods
- Quarterly revenue rose from $2.466 million to $3.663 million; net loss narrowed from $1.649 million to $0.839 million. Six-month revenue increased from $4.730 million to $6.603 million, while net loss narrowed from $4.024 million to $3.014 million.
- Six-month product gross margin improved to approximately 76%, compared with approximately 69% in the prior-year period, primarily reflecting a higher royalty rate from Innovacyn effective July 1, 2011. Management stated the rate increased from approximately 19% to approximately 30%.
- Six-month operating cash use fell to $1.468 million from $2.722 million, while investing cash use increased to $0.174 million from $0.053 million.
- Interest expense increased year over year, partly due to cash and non-cash interest on borrowings. A $0.218 million non-cash gain from the derivative-liability fair-value change reduced reported losses.
Outlook, risks, contingencies, and unusual items
- Management expects continued losses. It anticipated that existing cash plus a potential $1 million second loan tranche would fund working-capital needs through at least October 1, 2012. The tranche was available after milestones were met on September 30; the filing says management expected to borrow it before November 30, 2011. Additional financing was not committed, and unavailability could require spending cuts or delays to development.
- The June 2011 loan agreement provided up to $2.5 million: $1.5 million was borrowed, with a further $1 million conditional tranche. The loan is secured by company assets, including intellectual property; stated cash interest is 10%, with an effective rate of 13%. Warrants include a put feature that may require cash payment under specified circumstances.
- U.S. clearances did not authorize marketing Microcyn as a drug or with antimicrobial or wound-healing indications. Management said pivotal trials for U.S. drug commercialization would be delayed until a strategic partner or additional funding was secured.
- One customer accounted for 32% of quarterly revenue and 26% of six-month revenue. Revenue also relies on partners and distributors, and management cited regulatory, clinical, market-penetration, reimbursement, competitive, and financing uncertainties.
- A lawsuit filed in Mexico alleged, among other matters, conversion of assets, tortious interference, and defamation. The company said it considered the suit without merit, intended to defend itself, and had not accrued a loss reserve.
- Five executive employment agreements carried potential severance of $1.918 million. Subsequent to quarter-end, the CEO received a $170,000 cash bonus; directors agreed to accept fully vested stock options in lieu of cash compensation.
- Management reported disclosure controls and procedures were effective at the reasonable-assurance level and no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing names Oculus Innovative Sciences, Inc., not Sonoma Pharmaceuticals, Inc.
- Confirm whether and when the conditional $1 million loan tranche was drawn, and assess loan security, repayment terms, warrant dilution, and potential put-related cash obligations.
- Reconcile reported cash: the balance sheet and cash-flow statement show $3.622 million, while the MD&A cash-flow discussion states $3.662 million.
- Review customer concentration and the sustainability of revenue growth and the higher Innovacyn royalty rate.
- Track financing needs, clinical-trial timing and funding, U.S. regulatory status, and the outcome or financial exposure of the Mexico lawsuit.